SCHEMBL5036951

SCHEMBL5036951

O=C(Nc1ccccc1)c1nc(-c2ccc(Cl)cc2Cl)c(-c2ccc(Cl)cc2)s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 8/20 0.67
CNR2 P34972 3/20 0.62
MAPT P10636 4/20 0.48
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TMPRSS4 Q9NRS4 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PKM P14618 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PTGES O14684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4430376 0.84 CNR1 (0.65) CNR1CNR2MAPTALDH1A1KDM4E
SCHEMBL1250874 0.83 CNR1 (0.57) CNR1CNR2MAPTALDH1A1KDM4E
SCHEMBL5038585 0.81 CNR1 (0.64) CNR1CNR2
SCHEMBL5358211 0.80 CNR1 (1.00) CNR1CNR2PTGES
SCHEMBL5038528 0.79 CNR1 (0.61) CNR1CNR2
SCHEMBL5034172 0.78 CNR1 (0.67) CNR1CNR2NPC1RAB9A
SCHEMBL5038462 0.78 CNR1 (0.60) CNR1CNR2
SCHEMBL5038475 0.78 CNR1 (0.98) CNR1CNR2
SCHEMBL5034224 0.78 CNR1 (0.57) CNR1CNR2MAPTALDH1A1KDM4E
SCHEMBL5041590 0.77 CNR1 (0.68) CNR1CNR2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342032-B2 Thiazole derivatives having CB1-antagonistic, agonistic or partial agonistic activity SOLVAY PHARMACEUTICALS, INC. (NL) 2008-03-11 US disclosed
EP-1492779-A1 THIAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC, AGONISTIC OR PARTIAL AGONISTIC ACTIVITY Solvay Pharmaceuticals B.V. (NL) 2005-01-05 EP disclosed
US-20040266841-A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity ABBVIE B.V. (NL) 2004-12-30 US disclosed
WO-2003078413-A1 THIAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC, AGONISTIC OR PARTIAL AGONISTIC ACTIVITY SOLVAY PHARMACEUTICALS B.V. (NL) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266841-A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity CNR1, CNR2, CCKAR CNR1 1/4885CNR2 2/4885MAPT 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.